Regavirumab
Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.[1]
References
- ↑ Arizono, H; Sugano, T; Kaida, S; Shibusawa, K; Karasawa, Y; Esumi, Y; Kondo, S; Kiyoki, M (1994). "Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys". Arzneimittel-Forschung 44 (7): 909–13. PMID 7945531.
|
---|
| Fungal ("-fung-") | |
---|
| Viral ("-v(i)[r]-") | |
---|
| Bacterial ("-ba(c)-") | Human ("-bacu-") | |
---|
| Mouse ("-baco-") | |
---|
| | |
---|
| Humanized ("-bazu-") | |
---|
|
---|
| Toxin ("-tox(a)-") | Human ("-toxu-") | |
---|
| Chimeric ("-toxaxi-") | |
---|
| Humanized ("-toxazu-") | |
---|
|
---|
| |
|